GILEAD SCIENCES (GIS BE) stock market data APIs
€103.223
0(0%)
as of November 3, 2025
Try our APIs with
free plan!
GILEAD SCIENCES Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for GIS.BE.
Prev. Close
103.223
Open
103.223
High
103.223
Low
103.223
52 wk Range
80.5947-107.9042
Market Cap
78 028 M
Dividends (Yield)
0.0266
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GILEAD SCIENCES data using free add-ons & libraries
Get GILEAD SCIENCES Fundamental Data
GILEAD SCIENCES Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: 2.14
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GILEAD SCIENCES News
New
Gilead Sciences (GILD) Profit Margin Surge Reinforces Bullish Narratives on Operational Turnaround
Gilead Sciences (GILD) delivered a net profit margin of 27.9%, a sharp turnaround from just 0.4% a year ago, with earnings growth skyrocketing 6336.5% year over year. Looking ahead, management expects...
Closing Bell Movers: Amazon soars to all-time highs on earnings
In the opening hour of the evening session, U.S. equity futures are notably higher, with S&P 500 up 0.5% and Nasdaq 100 contracts up 1.0%. In commodities, WTI Crude Oil is little changed just above ...
Gilead Stock Reverses; Why Its Buy-Side Miss Isn't The End For Its New HIV Shot
Gilead stock reversed higher on smaller losses early Friday as analysts noted encouraging indicators for its newly approved HIV prevention shot. Continue Reading View Comments
GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow
Gilead Sciences, Inc. GILD posted better-than-expected third-quarter 2025 results and lifted the lower end of its product sales. Adjusted earnings per share (EPS) of $2.47 beat the Zacks Consensus Est...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
